Obviously, year-over-year in the first quarter that will drop to probably somewhere low double digits and it will be flattish in the second all other things being equal. It’s still an area of focus for us but to this point, there’s been a few large relationships under contract that have moved that needle. - President and CEO Although I that what’s important is when we get updates from our managed care folks, we’re asking them to aggressively still move forward and to get as many contracts as possible. And I think they’ve been getting positive contracts in terms of our contracting ability. So we have a good team there. There still is more to do there, but I think a lot of the big stuff has come in and it’s an area we like. So, we want to be the choice for managed care. I came out of that background and we have good relationships there and we want to be the solution there, particularly as Medicare Advantage outpaces traditional Medicare growth, we want to be there. - Obsidian Research Group Okay. Thanks. That’s helpful. And then is there a component of managed Medicaid that’s also a part of that from Medicaid expansion as a result of the Affordable Care Act as well? - Vice Chairman No. - Obsidian Research Group Okay. And then just moving on one other thing quickly. You guys mentioned that you’re kind of evaluating AMS3 and making some changes. Maybe if you’d expand on that a little bit? - President and CEO What we’re doing is we’ve actually been working quite hard. We’ve implemented AMS3 at 15 care sites. And the schedule when I first came in and looked at the schedule, it was very, very aggressive in terms of getting it rolled out in a two-year timeframe. We started to look at the difficulty with implementing AMS3 plus preparing for ICD10, and we can control our implementation on AMS3 and we can’t control when ICD10 is going to go. So our feeling is we want to make sure we get that right. We also want to see we have some fixes to do in terms of – AMS3 and we also want to see what the impact has been in the 15 centers we rolled out. - Obsidian Research Group Okay, that’s helpful. Thanks a lot. - President and CEO Sure.
Obviously, year-over-year in the first quarter that will drop to probably somewhere low double digits and it will be flattish in the second all other things being equal. It’s still an area of focus for us but to this point, there’s been a few large relationships under contract that have moved that needle. - President and CEO Although I that what’s important is when we get updates from our managed care folks, we’re asking them to aggressively still move forward and to get as many contracts as possible. And I think they’ve been getting positive contracts in terms of our contracting ability. So we have a good team there. There still is more to do there, but I think a lot of the big stuff has come in and it’s an area we like. So, we want to be the choice for managed care. I came out of that background and we have good relationships there and we want to be the solution there, particularly as Medicare Advantage outpaces traditional Medicare growth, we want to be there. - Obsidian Research Group Okay. Thanks. That’s helpful. And then is there a component of managed Medicaid that’s also a part of that from Medicaid expansion as a result of the Affordable Care Act as well? - Vice Chairman No. - Obsidian Research Group Okay. And then just moving on one other thing quickly. You guys mentioned that you’re kind of evaluating AMS3 and making some changes. Maybe if you’d expand on that a little bit? - President and CEO What we’re doing is we’ve actually been working quite hard. We’ve implemented AMS3 at 15 care sites. And the schedule when I first came in and looked at the schedule, it was very, very aggressive in terms of getting it rolled out in a two-year timeframe. We started to look at the difficulty with implementing AMS3 plus preparing for ICD10, and we can control our implementation on AMS3 and we can’t control when ICD10 is going to go. So our feeling is we want to make sure we get that right. We also want to see – we have some fixes to do in terms of AMS3 and we also want to see what the impact has been in the 15 centers we rolled out. - Obsidian Research Group Okay, that’s helpful. Thanks a lot. - President and CEO Sure.
2014-Amedisys-Earnings-Call.docx